Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA

Families of Spinal Muscular Atrophy announced today that Repligen Corporation RGEN has received approval from the U.S. Food and Drug Administration to commence a Phase I safety study in healthy volunteers for RG3039, formerly called Quinazoline495, which is being developed for Spinal Muscular Atrophy.